EGF and lung adenocarcinoma: Exogenous SP-D treatment has been shown to downregulate epidermal growth factor (EGF) signaling by preventing the binding of EGF to the EGF receptor (EGFR), hence suppressing the cell proliferation, invasion, and migration of A549 human lung adenocarcinoma cells (23).